Answers are grounded in this paper and cite their sources.
Glibenclamide is a widely used drug applied for the blockage of ATP-sensitive K+ channels (KATP channels) ubiquitously present in plasma membranes and mitochondria. While KATP channels opening was shown to be cytoprotective under variety of pathophysiological conditions, in certain cases KATP channel blockage is required for cell survival and the recovery of a living organism. However, in the literature glibenclamide application was shown to produce several adverse effects. In this work some aspects of glibenclamide treatment will be considered in relation to its adverse effects in mitochondria.
No takes yet. Share an insight, caveat, or question.
Akopova Ov (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: